---
title: "Feasibility Trial of Omega-3 Supplementation and Lipid Biomarkers in Youth with Migraine"
id: "medrxiv-1-omega-3-supplementation-with-lipid-biomarker-assessment-in-youth-with-migraine"
canonical_url: "https://medichelpline.com/clinical-feed/medrxiv-1-omega-3-supplementation-with-lipid-biomarker-assessment-in-youth-with-migraine"
content_type: "clinical_feed_article"
specialty: "Neurology"
source_name: "medRxiv (Clinical Preprints)"
source_url: "https://www.medrxiv.org/content/10.64898/2026.09.09.26362637v1?rss=1"
published_at: "2026-09-11T12:00:00.000Z"
evidence_level: "Verified Feed"
license: "CC-BY-NC-4.0 / Informational Use"
---
# Feasibility Trial of Omega-3 Supplementation and Lipid Biomarkers in Youth with Migraine
## Provenance & Clinical Metadata
- **Canonical URL:** https://medichelpline.com/clinical-feed/medrxiv-1-omega-3-supplementation-with-lipid-biomarker-assessment-in-youth-with-migraine
- **Specialty:** [Neurology](https://medichelpline.com/clinical-feed/neurology.md)
- **Primary Source:** medRxiv (Clinical Preprints)
- **Source URL:** [Original Journal Publication](https://www.medrxiv.org/content/10.64898/2026.09.09.26362637v1?rss=1)
- **Published At:** 2026-09-11T12:00:00.000Z
- **Evidence Rating:** Verified Feed
## Executive GIST (TL;DR)
- This quasi-randomized, double-blind, placebo-controlled feasibility trial enrolled children and adolescents aged 10–17 years with migraine to test procedures for an omega-3 nutrition intervention. - Participants were sequentially allocated 1:1 to daily **omega-3** supplementation (850 mg EPA + DHA) or matched coconut oil placebo for 12 weeks. - The study integrated longitudinal **dried blood spot** biomarker collection, four 24-hour dietary recalls, validated patient-reported outcome measures, and caregiver acceptability assessments. - Post-hoc feasibility benchmarks were set from pediatric trial literature: recruitment >70% of target, retention ≥70%, supplement adherence ≥70% (caregiver report), biospecimen completion ≥90%, dietary recall completion ≥80%, and acceptability ≥70% favorable. - Of 58 assessed, 57 were enrolled and allocated (29 intervention, 28 placebo); 44 participants (77%) completed 12-week follow-up (22 per group), meeting the retention benchmark. - Dried blood spot collection was completed at both time points for all participants who attended visits (100% completion). - All 44 study completers completed all four planned dietary recalls (100% completion). - Caregiver-reported acceptability was high; most caregivers rated daily supplement administration acceptable and were open to future dietary supplement use for migraine management. - Thirteen participants discontinued: five withdrew, five lost to follow-up, two stopped because of supplement palatability, one became ineligible. - Structured telephone follow-up at weeks 4 and 8 supported retention and adherence monitoring. - All six post-hoc feasibility benchmarks were met. The authors conclude the protocol is feasible and acceptable and recommend progression to a larger randomized trial with concealed randomization, prospective daily headache diaries, and longer intervention duration. - Trial registration: ClinicalTrials.gov NCT06899074 (registered 20 March 2025).
## Clinical Analysis & Structured Key Points
[](https://www.medrxiv.org/cdn-cgi/content?id=Q57ExhsZNXIuP2XxuX.0UhB3HM.ku6f9xzGK2i_IRrk-1789179988.8106759-1.2.1.1-3mAtkYdFOg88N_76W8yp93VoQA_vBDAML3bANTC23lHnguu9F6pA_ot4ORt.edH0) [Skip to main content](https://www.medrxiv.org/content/10.64898/2026.09.09.26362637v1?rss=1#main-content) [![medRxiv](https://www.medrxiv.org/sites/default/files/medrxiv_inner_logo.png)](https://www.medrxiv.org/) * [Home](https://www.medrxiv.org/) * [Submit](https://www.medrxiv.org/submit-a-manuscript) * [FAQ](https://www.medrxiv.org/about/FAQ) * [Blog](https://connect.medrxiv.org/news/) * [ALERTS / RSS](https://www.medrxiv.org/content/alertsrss) * [Resources](https://connect.medrxiv.org/resources/) * [About](https://www.medrxiv.org/content/about-medrxiv) Search for this keyword [Advanced Search](https://www.medrxiv.org/search) Follow this preprint # Omega-3 Supplementation with Lipid Biomarker Assessment in Youth with Migraine: A Quasi-Randomized Controlled Feasibility Trial [ View ORCID Profile](http://orcid.org/0009-0000-9405-703X)Jaclyn Bain, [ View ORCID Profile](http://orcid.org/0000-0003-2114-5156)Daisy Zamora, [ View ORCID Profile](http://orcid.org/0000-0001-6122-7821)Keturah R. Faurot, [ View ORCID Profile](http://orcid.org/0000-0003-1950-2521)Saame Raza Shaikh, [ View ORCID Profile](http://orcid.org/0000-0003-2607-9514)Anne E. Sanders, Samantha Glover, [ View ORCID Profile](http://orcid.org/0000-0002-9314-8076)Klaus Werner, [ View ORCID Profile](http://orcid.org/0000-0002-1068-9951)Steven P. Trau, [ View ORCID Profile](http://orcid.org/0000-0003-1290-7251)Kimon Divaris, [ View ORCID Profile](http://orcid.org/0000-0001-9295-9849)Caroline M. Sawicki doi: https://doi.org/10.64898/2026.09.09.26362637 [This article is a preprint and has not been certified by peer review [](https://www.medrxiv.org/about/FAQ#unrefereed)[what does this mean?](https://www.medrxiv.org/about/FAQ#unrefereed)]. It reports new medical research that has yet to be evaluated and so should _not_ be used to guide clinical practice. Jaclyn Bain 1 University of North Carolina, Chapel Hill; * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Jaclyn%2BBain%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Bain%20J&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3AJaclyn%2BBain%2B) * [ORCID record for Jaclyn Bain](http://orcid.org/0009-0000-9405-703X "Open in new tab") Daisy Zamora 1 University of North Carolina, Chapel Hill; * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Daisy%2BZamora%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Zamora%20D&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3ADaisy%2BZamora%2B) * [ORCID record for Daisy Zamora](http://orcid.org/0000-0003-2114-5156 "Open in new tab") Keturah R. Faurot 1 University of North Carolina, Chapel Hill; * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Keturah%2BR.%2BFaurot%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Faurot%20KR&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3AKeturah%2BR.%2BFaurot%2B) * [ORCID record for Keturah R. Faurot](http://orcid.org/0000-0001-6122-7821 "Open in new tab") Saame Raza Shaikh 1 University of North Carolina, Chapel Hill; * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Saame%2BRaza%2BShaikh%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Shaikh%20SR&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3ASaame%2BRaza%2BShaikh%2B) * [ORCID record for Saame Raza Shaikh](http://orcid.org/0000-0003-1950-2521 "Open in new tab") Anne E. Sanders 1 University of North Carolina, Chapel Hill; * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Anne%2BE.%2BSanders%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Sanders%20AE&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3AAnne%2BE.%2BSanders%2B) * [ORCID record for Anne E. Sanders](http://orcid.org/0000-0003-2607-9514 "Open in new tab") Samantha Glover 1 University of North Carolina, Chapel Hill; * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Samantha%2BGlover%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Glover%20S&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3ASamantha%2BGlover%2B) Klaus Werner 2 Duke University * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Klaus%2BWerner%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Werner%20K&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3AKlaus%2BWerner%2B) * [ORCID record for Klaus Werner](http://orcid.org/0000-0002-9314-8076 "Open in new tab") Steven P. Trau 1 University of North Carolina, Chapel Hill; * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Steven%2BP.%2BTrau%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Trau%20SP&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3ASteven%2BP.%2BTrau%2B) * [ORCID record for Steven P. Trau](http://orcid.org/0000-0002-1068-9951 "Open in new tab") Kimon Divaris 1 University of North Carolina, Chapel Hill; * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Kimon%2BDivaris%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Divaris%20K&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3AKimon%2BDivaris%2B) * [ORCID record for Kimon Divaris](http://orcid.org/0000-0003-1290-7251 "Open in new tab") Caroline M. Sawicki 1 University of North Carolina, Chapel Hill; * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Caroline%2BM.%2BSawicki%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Sawicki%20CM&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3ACaroline%2BM.%2BSawicki%2B) * [ORCID record for Caroline M. Sawicki](http://orcid.org/0000-0001-9295-9849 "Open in new tab") * For correspondence: caroline_sawicki@unc.edu * [Abstract](https://www.medrxiv.org/content/10.64898/2026.09.09.26362637v1)[](https://www.medrxiv.org/panels_ajax_tab/biorxiv_tab_art/node:1298456/1) * [Info/History](https://www.medrxiv.org/content/10.64898/2026.09.09.26362637v1.article-info)[](https://www.medrxiv.org/panels_ajax_tab/biorxiv_tab_info/node:1298456/1) * [Metrics](https://www.medrxiv.org/content/10.64898/2026.09.09.26362637v1.article-metrics)[](https://www.medrxiv.org/panels_ajax_tab/article_tab_metrics/node:1298456/1) * [Supplementary material](https://www.medrxiv.org/content/10.64898/2026.09.09.26362637v1.supplementary-material)[](https://www.medrxiv.org/panels_ajax_tab/biorxiv_tab_data/node:1298456/1) * [Data/Code](https://www.medrxiv.org/content/10.64898/2026.09.09.26362637v1.external-links)[](https://www.medrxiv.org/panels_ajax_tab/article_tab_data_code/node:1298456/1) * [ Preview PDF](https://www.medrxiv.org/content/10.64898/2026.09.09.26362637v1.full.pdf+html)[](https://www.medrxiv.org/panels_ajax_tab/biorxiv_tab_pdf/node:1298456/1) ![Loading](https://www.medrxiv.org/sites/all/modules/contrib/panels_ajax_tab/images/loading.gif) ## Abstract Background: Omega-3 polyunsaturated fatty acids may modulate lipid-mediated inflammatory pathways implicated in migraine, yet pediatric trial methodologies evaluating biologic target engagement remain limited. This study evaluated the feasibility of conducting a pediatric nutrition-based migraine intervention trial integrating longitudinal dried blood spot biomarker collection, validated patient-reported outcome measures, dietary assessment, and caregiver-reported acceptability measures. Methods: A quasi-randomized, double-blind, placebo-controlled feasibility trial was conducted at two academic pediatric neurology clinics. Children and adolescents aged 10-17 years with migraine were assigned 1:1 using sequential alternating allocation to daily omega-3 supplementation (850 mg eicosapentaenoic acid + docosahexaenoic acid) or matched coconut oil placebo for 12 weeks. Feasibility outcomes included recruitment yield, participant retention, caregiver-reported supplement adherence, dried blood spot biospecimen completion, 24-hour dietary recall completion, and intervention acceptability assessed via caregiver exit questionnaire. Feasibility benchmarks were established post hoc based on published pediatric trial literature: recruitment >70% of target sample, retention ≥70%, supplement adherence ≥70% of caregivers reporting administration on most days, biospecimen completion ≥90%, dietary recall completion ≥80%, and acceptability rated favorably by ≥70% of caregivers. Clinical efficacy outcomes will be reported separately. Results: Of 58 individuals assessed for eligibility, 57 were enrolled and allocated (29 intervention, 28 placebo). Forty-four participants (77%) completed the 12-week follow-up (22 per group), meeting the retention benchmark. Dried blood spot collection was completed at both time points for all participants who attended study visits (100%). All 44 study completers finished all four planned dietary recalls (100% completion). Caregiver-reported acceptability was high, with the majority rating daily supplement administration as acceptable and reporting openness to future dietary supplement use for migraine management. Thirteen participants discontinued: five withdrew, five were lost to follow-up, two discontinued due to supplement palatability, and one no longer met inclusion criteria. Structured telephone follow-up at weeks 4 and 8 supported retention and adherence monitoring. Conclusions: This feasibility trial demonstrated that a pediatric nutrition-based migraine intervention integrating dried blood spot biomarker collection, repeated dietary recalls, validated patient-reported outcomes, and structured remote follow-up is feasible and acceptable to families. All six post-hoc feasibility benchmarks were met. Findings support progression to a larger-scale randomized controlled trial with modifications including concealed randomization, prospective daily headache diaries, and longer intervention duration. Trial registration: ClinicalTrials.gov, [NCT06899074](https://www.medrxiv.org/lookup/external-ref?link_type=CLINTRIALGOV&access_num=NCT06899074&atom=%2Fmedrxiv%2Fearly%2F2026%2F09%2F11%2F2026.09.09.26362637.atom). Registered 20 March 2025. ### Competing Interest Statement The authors have declared no competing interest. ### Clinical Trial NCT06899074 ### Author Declarations I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained. Yes The details of the IRB/oversight body that provided approval or exemption for the research described are given below: The Ethics committee/IRB of University of North Carolina gave ethical approval for this work. I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals. Yes I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance). Yes I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable. Yes ## Data Availability All data produced in the present study are available upon reasonable request to the authors. ## Funder Information Declared National Institute of Diabetes and Digestive and Kidney Diseases, https://ror.org/00adh9b73, P30DK056350 Nutrition Obesity Research Center, Chapel Hill, NC Copyright The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a [CC-BY-NC-ND 4.0 International license](http://creativecommons.org/licenses/by-nc-nd/4.0/). bioRxiv and medRxiv thank the following for their generous financial support: > The Chan Zuckerberg Initiative, Cold Spring Harbor Laboratory, the Sergey Brin Family Foundation, California Institute of Technology, Centre National de la Recherche Scientifique, Fred Hutchinson Cancer Center, Imperial College London, Massachusetts Institute of Technology, Stanford University, The University of Edinburgh, University of Washington, and Vrije Universiteit Amsterdam. [Donate to openRxiv ](https://www.zeffy.com/en-US/donation-form/donate-to-make-a-difference-10981) [ Back to top](https://www.medrxiv.org/content/10.64898/2026.09.09.26362637v1?rss=1#page) [ Previous](https://www.medrxiv.org/content/10.64898/2026.09.10.26362699v1 "DualStream-MTCA: A Hybrid Deep Learning Model for the Simultaneous Early Detection of Sepsis and Heart Failure in Adult Intensive Care")[Next ](https://www.medrxiv.org/content/10.64898/2026.09.09.26362610v1 "Access to assistive products, home modifications and human help in older adults in the 2021-2025 Autonomy survey") Posted September 11, 2026. [ Download PDF](https://www.medrxiv.org/content/10.64898/2026.09.09.26362637v1.full.pdf) Print/Save Options [Download PDF](https://www.medrxiv.org/content/medrxiv/early/2026/09/11/2026.09.09.26362637.full.pdf)Full Text & In-line FiguresXML [More Info](https://www.medrxiv.org/about/FAQ#PrintOptions "More Information on Print/Save Options") [ Author Declarations](https://www.medrxiv.org/content/10.64898/2026.09.09.26362637v1#p-5) [Supplementary Material ](https://www.medrxiv.org/content/10.64898/2026.09.09.26362637v1.supplementary-material) [ Data/Code](https://www.medrxiv.org/content/early/2026/09/11/2026.09.09.26362637.external-links) [ Email](https://www.medrxiv.org/ "Email this Article") [ Share](https://www.medrxiv.org/) Omega-3 Supplementation with Lipid Biomarker Assessment in Youth with Migraine: A Quasi-Randomized Controlled Feasibility Trial Jaclyn Bain, Daisy Zamora, Keturah R. Faurot, Saame Raza Shaikh, Anne E. Sanders, Samantha Glover, Klaus Werner, Steven P. Trau, Kimon Divaris, Caroline M. Sawicki medRxiv 2026.09.09.26362637; doi: https://doi.org/10.64898/2026.09.09.26362637 [This article is a preprint and has not been certified by peer review [](https://www.medrxiv.org/about/FAQ#unrefereed)[what does this mean?](https://www.medrxiv.org/about/FAQ#unrefereed)]. It reports new medical research that has yet to be evaluated and so should _not_ be used to guide clinical practice. Share This Article: Copy [![Twitter logo](https://www.medrxiv.org/sites/all/modules/highwire/highwire/images/twitter.png)](https://www.medrxiv.org/highwire_log/share/twitter?link=http%3A%2F%2Ftwitter.com%2Fshare%3Furl%3Dhttps%253A%2F%2Fwww.medrxiv.org%2Fcontent%2F10.64898%2F2026.09.09.26362637v1%26text%3DOmega-3%2520Supplementation%2520with%2520Lipid%2520Biomarker%2520Assessment%2520in%2520Youth%2520with%2520Migraine%253A%2520A%2520Quasi-Randomized%2520Controlled%2520Feasibility%2520Trial "Share this on Twitter") [![Facebook logo](https://www.medrxiv.org/sites/all/modules/highwire/highwire/images/fb-blue.png)](https://www.medrxiv.org/highwire_log/share/facebook?link=http%3A%2F%2Fwww.facebook.com%2Fsharer.php%3Fu%3Dhttps%253A%2F%2Fwww.medrxiv.org%2Fcontent%2F10.64898%2F2026.09.09.26362637v1%26t%3DOmega-3%2520Supplementation%2520with%2520Lipid%2520Biomarker%2520Assessment%2520in%2520Youth%2520with%2520Migraine%253A%2520A%2520Quasi-Randomized%2520Controlled%2520Feasibility%2520Trial "Share on Facebook") [![LinkedIn logo](https://www.medrxiv.org/sites/all/modules/highwire/highwire/images/linkedin-32px.png)](https://www.medrxiv.org/highwire_log/share/linkedin?link=http%3A%2F%2Fwww.linkedin.com%2FshareArticle%3Fmini%3Dtrue%26url%3Dhttps%253A%2F%2Fwww.medrxiv.org%2Fcontent%2F10.64898%2F2026.09.09.26362637v1%26title%3DOmega-3%2520Supplementation%2520with%2520Lipid%2520Biomarker%2520Assessment%2520in%2520Youth%2520with%2520Migraine%253A%2520A%2520Quasi-Randomized%2520Controlled%2520Feasibility%2520Trial%26summary%3D%26source%3DmedRxiv "Publish this post to LinkedIn") [![Mendeley logo](https://www.medrxiv.org/sites/all/modules/highwire/highwire/images/mendeley.png)](https://www.medrxiv.org/highwire_log/share/mendeley?link=http%3A%2F%2Fwww.mendeley.com%2Fimport%2F%3Furl%3Dhttps%253A%2F%2Fwww.medrxiv.org%2Fcontent%2F10.64898%2F2026.09.09.26362637v1%26title%3DOmega-3%2520Supplementation%2520with%2520Lipid%2520Biomarker%2520Assessment%2520in%2520Youth%2520with%2520Migraine%253A%2520A%2520Quasi-Randomized%2520Controlled%2520Feasibility%2520Trial "Share on Mendeley") [ Citation Tools](https://www.medrxiv.org/ "Citation Tools") [ Get QR code](https://connect.medrxiv.org/qr/2026.09.09.26362637) * [Tweet Widget](http://twitter.com/share?url=https%3A//www.medrxiv.org/content/10.64898/2026.09.09.26362637v1&count=horizontal&via=&text=Omega-3%20Supplementation%20with%20Lipid%20Biomarker%20Assessment%20in%20Youth%20with%20Migraine%3A%20A%20Quasi-Randomized%20Controlled%20Feasibility%20Trial&counturl=www.medrxiv.org/content/10.64898/2026.09.09.26362637v1 "Tweet This") Reviews and Context 0 Comment 0 TRIP Peer Reviews 0 Community Reviews 0 Automated Services 0 Blogs/Media 0 Author Videos **Subject Areas** [**All Articles**](https://www.medrxiv.org/content/early/recent) * [Addiction Medicine](https://www.medrxiv.org/collection/addiction-medicine) (616) * [Allergy and Immunology](https://www.medrxiv.org/collection/allergy-and-immunology) (898) * [Anesthesia](https://www.medrxiv.org/collection/anesthesia) (330) * [Cardiovascular Medicine](https://www.medrxiv.org/collection/cardiovascular-medicine) (4800) * [Dentistry and Oral Medicine](https://www.medrxiv.org/collection/dentistry-and-oral-medicine) (478) * [Dermatology](ht
## Related Clinical Research

- [Capricor’s deramiocel for Duchenne appears headed for FDA rejection](https://medichelpline.com/clinical-feed/stat-news-1-stat-capricor-therapeutics-duchenne-treatment-is-heading-for-an-fda-rejection.md)
- [New study links tau to mitochondrial reverse electron transport in Alzheimer’s models](https://medichelpline.com/clinical-feed/stat-news-0-stat-study-reveals-new-role-for-tau-a-top-target-for-alzheimer-s-drug.md)
- [KERENDIA FDA Approval for CKD in Type 1 Diabetes and Arrowhead’s Plozasiran SHASTA-3/4 Phase 3 Res](https://medichelpline.com/clinical-feed/endocrine-news-0-pharma-friday-september-18-2026.md)
- [Real-world uptake of SGLT2 inhibitors in heart failure across ejection fraction: Swedish registry](https://medichelpline.com/clinical-feed/pubmed-42001463.md) (DOI: 10.1093/ehjqcco/qcag063)
- [SGLT2 inhibitors and outcomes across cardio‑reno‑metabolic disease by BMI: a randomized trials met](https://medichelpline.com/clinical-feed/pubmed-41948998.md) (DOI: 10.1093/ehjqcco/qcag061)

## Navigation
- [← Back to Neurology Feed](https://medichelpline.com/clinical-feed/neurology.md)
- [← All Clinical Specialties](https://medichelpline.com/clinical-feed.md)
## Medical & Regulatory Disclaimer

> [!CAUTION]
> MedicHelpline content is structured for research, educational, and professional discovery purposes. It does not constitute individual medical advice, clinical diagnosis, or treatment recommendations.
> Always verify dosing, contraindications, and regulatory alerts against official product labeling and primary regulatory sources before clinical decision-making.